Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study

Joanne R Morling, Jonathan A Fallowfield, Rachel M Williamson, Lisa D Nee, Andrew P Jackson, Stephen Glancy, Rebecca M Reynolds, Peter C Hayes, Indra N Guha, Mark W J Strachan, Jackie F Price

Research output: Contribution to journalArticlepeer-review

Abstract

Type 2 diabetes is an established risk factor for the presence and progression of fatty liver. Little is known about the distributions and correlates of hepatic non-invasive biomarkers in community-based populations with diabetes, unselected for liver disease. We aimed to identify the distribution of, and metabolic risk factors associated with serum cytokeratin-18 (CK18) and the Enhanced Liver Fibrosis score (ELF), in a large, representative cohort of people with type 2 diabetes (the Edinburgh Type 2 Diabetes Study, ET2DS).
Original languageEnglish
Pages (from-to)1267-1277
JournalLiver International
Volume34
Issue number8
Early online date15 Nov 2013
DOIs
Publication statusPublished - Sep 2014

Fingerprint

Dive into the research topics of 'Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study'. Together they form a unique fingerprint.

Cite this